Mckesson Corp (MCK)
Juste valeurFondamental
79
Prix
$890.58
Capitalisation boursière
$99.84B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 septembre 2026 with claude-haiku-4-5 — shared with all users
McKesson's 10-K names Cencora as one of its two largest competitors: both are national full-line wholesalers distributing branded, generic and specialty drugs to the same U.S. pharmacy chains, health systems and physician practices.
The other of the two competitors McKesson names by name: Cardinal Health bids for the same U.S. drug-distribution contracts and also sells medical-surgical supplies to the same hospitals and surgery centers.
Henry Schein's own 10-K names McKesson as one of its two primary national competitors in the medical market, where both supply consumables and equipment to office-based physicians and dental practices.
Privately held national distributor of medical-surgical supplies, competing head-on with McKesson Medical-Surgical for hospital, surgery-centre and physician-office supply contracts.
Distributor of medical-surgical products to U.S. acute-care hospitals and health systems, bidding for the same supply-chain contracts as McKesson's Medical-Surgical Solutions segment.
Privately held regional full-line pharmaceutical wholesaler in the U.S. South, serving the independent pharmacies and regional hospital groups that McKesson also supplies.
Bilan & Liquidités
Chiffre d'affaires
$410.98B
12 derniers mois (au 30/06/2026)
Résultat net
$4.59B
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$5.72B
Capitaux propres totaux
$-2.17B
Passif total
$84.10B
Ratio de liquidité général
0.89
Couverture des intérêts
23.62
Dette/EBITDA
1.80
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$911.16
Prix actuel
$890.58
Marge de sécurité
+2.3%
Fourchette de juste valeur
$662.92 - $1159.40
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
22.90
ROE
-219.2%
Ratio P/B
-
P/FCF
15.52
Marge brute
3.6%
ROIC
28.5%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
28.5%
WACC
7.3%
ROIC − WACC
+21.2 pp
Le ROIC dépasse le coût du capital — l'entreprise crée de la valeur pour les actionnaires.
Critères d'analyse fondamentale
Réussi (19)
- EPS shows upward trend
- EPS CAGR 14.57%
- Price CAGR 20.17%
- ROIC 28.5%
- P/FCF 15.52
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 39.4%
- Revenue Growth 5Y 11.1%
- Analyst Consensus 79% Buy
- Earnings Surprise avg 2.9%
- Earnings Quality (OCF/NI) 1.49
- Share Dilution -3.1%
- Net Margin Trend 1.1% vs 0.8%
- Piotroski F-Score 7/9
Échoué (4)
- Gross Margin 3.6%
- Operating Margin 1.6%
- Low reliance on intangibles
- DCF valuation (Overvalued)
Indisponible (5)
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Brian S. Tyler Ph.D. | CEO & Chairman | 58 |
| Ms. Michele Lau J.D. | Executive VP & Chief Legal Officer | 49 |
| Ms. LeAnn B. Smith | Executive VP & Chief Human Resources Officer | 50 |
| Mr. Kenny K. Cheung | Executive VP & CFO | 43 |
| Mr. Napoleon B. Rutledge Jr. | Senior VP, Controller & Chief Accounting Officer | 52 |
| Paula Adkison | Senior Vice President of Corporate Finance, Investor Relations & Strategic Finance | - |
| Mr. Francisco J. Fraga | Executive VP, Chief Information Officer & CTO | 52 |
| Ms. Jeni Dominguez | Head of Investor Relations | - |
| Mr. Kirk Kaminsky | Executive VP & Group President of North American Pharmaceutical Services | - |
| Mr. Stanton J. McComb | President of Medical-Surgical | - |
Risque d'audit
9
Risque du conseil
6
Risque de rémunération
1
Risque droits des actionnaires
4
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-05-08
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-08-05
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-08-28
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for MCK, sourced from Markets Gazette.
- 6/3/2026NEUTRALMcKesson Unit Prices $2.25 Billion Leveraged Loan Ahead of IPO
McKesson Corp.'s medical-surgical unit has priced a $2.25 billion leveraged loan. This move precedes the unit's anticipated initial public offering (IPO). While the loan issuance itself is a financing activity, its direct impact on McKesson's stock price is neutral at this stage. The successful pricing indicates market appetite for the unit's debt, which could be a positive precursor to the IPO, but the primary focus remains on the upcoming equity offering rather than the debt itself for immediate trading signals.
- 4/8/2026POSITIVEHere's How Much $100 Invested In McKesson 20 Years Ago Would Be Worth Today
An investment of $100 in McKesson Corporation (MCK) twenty years ago would have grown to approximately $1,640 today, representing a significant 16.4x return. This performance indicates a strong compound annual growth rate (CAGR) over the past two decades, outperforming many market benchmarks. The sustained growth suggests effective business strategy, operational efficiency, and favorable market positioning within the healthcare distribution sector. For investors, this historical data highlights McKesson's long-term value creation potential and its resilience through various economic cycles.
via Markets Gazette